High-flow nasal oxygen therapy in acute respiratory failure


Submitted: 3 September 2018
Accepted: 1 October 2018
Published: 16 October 2018
Abstract Views: 1128
PDF: 435
HTML: 169
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

High-flow nasal cannula (HFNC) is a new effective device, which is able to deliver oxygen-therapy at a reliable FiO2 but also a certain amount of respiratory assistance; however HFNC could not be defined as a mechanical ventilator. The main physiologic advantage as compared to conventional oxygen therapy (COT) is the capability of HFNC to meet the increased ventilator demand in patients with respiratory distress and therefore reduce the amount of respiratory muscle’s workload. The main clinical advantage over both COT and noninvasive ventilation (NIV) is the greater comfort and acceptability reported by patients. So far there are several indications for HFNC use both in and outside ICU especially for milder hypoxemic spontaneously breathing patients and prevention of extubation failure in intubated patients, as well as palliative care in end stage neoplastic and nonneoplastic respiratory diseases. A large proportion of potential HFNC candidates belongs to advanced age people. Caution should be taken in the selection of the patients, monitoring, escalating treatment and setting of aplication.

Scala, R. (2018). High-flow nasal oxygen therapy in acute respiratory failure. Geriatric Care, 4(3). https://doi.org/10.4081/gc.2018.7799

Downloads

Download data is not yet available.

Citations


Similar Articles

You may also start an advanced similarity search for this article.